Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
NATHBIOGEN

Nath Bio-Genes (India) Share Price

 

 

Nath Bio-Genes (India) live price: ₹172. It opened at ₹176 vs previous close ₹174; intraday high/low: ₹178/₹171. The 50 & 200 DMA stand at ₹154.19/₹160.35.

Nath Bio-Genes (India) Performance

  • Today's Low
  • ₹171
  • Today's High
  • ₹178
  • 52 Week Low
  • ₹126
  • 52 Week High
  • ₹239
  • Open Price₹176
  • Previous Close₹174
  • Volume9,043
  • 50 DMA₹154.19
  • 100 DMA₹154.25
  • 200 DMA₹160.35

Nath Bio-Genes (India) Chart

Investment Returns

  • Over 1 Month + 32.02%
  • Over 3 Month + 23.75%
  • Over 6 Month + 1.34%
  • Over 1 Year + 7.82%

Smart Investing Starts Here Start SIP with Nath Bio-Genes (India) for Steady Growth!

Invest Now

Nath Bio-Genes (India) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 7.6
  • PEG Ratio
  • 0.9
  • Market Cap Cr
  • 327
  • P/B Ratio
  • 0.5
  • Average True Range
  • 7.6
  • EPS
  • 20.49
  • Dividend Yield
  • 1.2
  • MACD Signal
  • 6.69
  • RSI
  • 66.12
  • MFI
  • 83.54

Nath Bio-Genes (India) Financials

Nath Bio-Genes (India) Technicals

EMA & SMA

Current Price
₹172.00
-1.78 (-1.02%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹161.77
  • 50 Day
  • ₹154.19
  • 100 Day
  • ₹154.25
  • 200 Day
  • ₹160.35

Resistance and Support

173.48 Pivot Speed
  • R3 183.86
  • R2 180.89
  • R1 176.45
  • S1 169.04
  • S2 166.07
  • S3 161.63

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Nath Bio Genes India has an operating revenue of Rs. 445.48 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 11% is healthy, ROE of 5% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 16% and 6% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 73 which is a FAIR score but needs to improve its earnings, a RS Rating of 75 which is FAIR indicating the recent price performance, Buyer Demand at C which is evident from recent supply seen, Group Rank of 4 indicates it belongs to a strong industry group of Agricultural Operations and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Nath Bio-Genes (India) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-04 Audited Results & Final Dividend
2026-01-31 Quarterly Results
2025-11-13 Quarterly Results
2025-07-11 Quarterly Results
2025-04-29 Audited Results & Final Dividend
Date Purpose Remarks
2025-08-14 FINAL Rs.2.00 per share(20%)Final Dividend
2024-08-09 FINAL Rs.2.00 per share(20%)Final Dividend
View Nath Bio-Genes (India) Dividend History Arrow

Nath Bio-Genes (India) F&O

Nath Bio-Genes (India) Shareholding Pattern

45.6%
0.01%
0.22%
0%
34.4%
19.77%

Nath Bio-Genes (India) FAQs

Nath Bio-Genes (India) share price is ₹172 As on 29 April, 2026 | 06:33

The Market Cap of Nath Bio-Genes (India) is ₹326.9 Cr As on 29 April, 2026 | 06:33

The P/E ratio of Nath Bio-Genes (India) is 7.6 As on 29 April, 2026 | 06:33

The PB ratio of Nath Bio-Genes (India) is 0.5 As on 29 April, 2026 | 06:33

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23